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Abstract
Background: This paper evaluates psychometric properties of a recently developed measure
focusing on the health-related quality of life (HRQL) of long-term cancer survivors, the Quality of
Life in Adult Survivors scale (QLACS), in a sample of breast cancer survivors. This represents an
important area of study, given the large number of breast cancer patients surviving many years post
diagnosis.
Methods: Analyses are based on an 8-year follow-up of a sample of breast cancer survivors who
participated in an earlier study conducted in 1995. Participants were re-contacted in 2003 and
those who were reachable and agreed to participate (n = 94) were surveyed using a variety of
measures including the QLACS. Additional follow-up surveys were conducted 2 weeks and one
year later. Psychometric tests of the QLACS included test-retest reliability, concurrent and
retrospective validity, and responsiveness.
Results: The QLACS domain and summary scores showed good test-retest reliability (all test-
retest correlations were above .7) and high internal consistency. The Generic Summary Score
showed convergent validity with other measures designed to assess generic HRQL. The Cancer-
Specific Summary score exhibited divergent validity with generic HRQL measures, but not a cancer-
related specific measure. The QLACS Cancer-Specific Summary Score demonstrated satisfactory
predictive validity for factors that were previously shown to be correlated with HRQL. The
QLACS generally demonstrated a high level of responsiveness to life changes.
Conclusion: The QLACS may serve as a useful measure for assessing HRQL among long-term
breast cancer survivors that are not otherwise captured by generic measures or those specifically
designed for newly diagnosed patients.
Background
The importance of quality of life issues for cancer patients
is well-recognized by both researchers and clinicians [1-
3]. Over the past several decades numerous studies have
addressed the physical, emotional, social, and sexual well-
being of cancer patients with the focus largely on the
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period of treatment following diagnosis. With improved
early detection and treatment, large numbers of breast
cancer patients are now surviving many years post diagno-
sis. Sixty-four percent of adults diagnosed with cancer
today will be alive five years after their diagnosis [4], while
88% of women diagnosed with breast cancer will be alive
5 years after diagnosis and 80% will be alive after 10 years
[4]. The large number of women surviving many years
post breast cancer diagnosis has heightened interest in
studying long-term effects of cancer on quality of life
[5,6]. Research suggesting that cancer treatments can have
long-term physical, psychological, sexual and cognitive
effects that may influence quality of life has added to this
interest [5,7-12].
Long-term consequences of breast cancer include issues
present after diagnosis and treatment that linger, but also
new concerns that develop over time [9]. Conditions that
continue after treatment are pain and fatigue
[10,11,13,14], sexual problems [8] and appearance and
body-image concerns [6]. Psychological dysfunction can
also be a problem [5,8,15]. Newer issues that may develop
include insurance concerns, worry about the health of
children, and worry about the family's future in the event
of recurrence [6,11,15]. Late physical effects of cancer
treatment, such as cardiac toxicity or development of sec-
ond malignancies have also been identified [16,17]. It is
also important to recognize that it is not uncommon for
people to report positive outcomes of cancer such as bet-
ter personal relationships, a change in priorities, and
greater appreciation for life [18-22].
A number of cancer-specific health-related quality of life
(HRQL) measures have been developed, such as the Func-
tional Adjustment to Cancer Therapy (FACT) [23], Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) [24], Functional Living Index-Cancer (FLIC)
[25], and the Cancer Rehabilitation Evaluation System
(CaRES) [26]. These measures, however, were designed to
capture acute effects of being newly diagnosed with cancer
and the immediate effects of surgery and treatment and
may not be appropriate for use with long-term survivors.
Despite the importance of HRQL for long-term survivors,
there are currently only two HRQL measures designed
specifically for long-term survivors, one of which is a
modification of the other [15,27]. Both of these scales
have limitations in terms of item wording and HRQL
domains. The Quality of Life in Adult Cancer Survivor
scale (QLACS) is a recently developed measure specifically
focusing on the quality of life of long-term cancer survi-
vors [22] that was developed in response to these limita-
tions. The QLACS is based on a conceptualization of
cancer-related quality of life provided by Gotay et al. [2]
as the state of well being that is a composite of two com-
ponents: the ability to perform everyday activities that
reflect physical, psychological, and social well-being; and
patient satisfaction with levels of functioning and control
of the disease. This conceptualization takes into account
both functioning and patient satisfaction with function-
ing and views QOL as a multidimensional construct.
We have previously described the development of the
QLACS and some of its psychometric properties (e.g.,
internal consistency, validity) [22,28]. Initial psychomet-
ric evaluation has shown that the instrument has good
reliability and face and content validity. The present paper
provides an additional evaluation of the QLACS based on
data from a follow-up study of breast cancer survivors.
This study examined test-retest reliability, responsiveness
to change, and additional validity of the QLACS.
Methods
Study design and sample selection
The present analyses are based on an 8-yr. follow-up of a
sample of younger breast cancer survivors who partici-
pated in an earlier study [29,29]. The original study was
funded as part of a project to specifically study younger
women (≤ age 50) with breast cancer. In the original
study, women diagnosed with breast cancer within the
past 3 years were recruited from six hospitals in the
Greater Boston and New Hampshire areas in 1995. At that
time, each institution reviewed their medical records and
identified all women who were diagnosed with their first
breast cancer in the previous 3 years, were at least 4
months post diagnosis, and were aged 50 or under at the
time of diagnosis. Only women who had stage I, II, or III
breast cancer were included. The Institutional Review
Board of all Institutions reviewed and approved the pro-
tocol. The total sample of completed interviews was 202
women. Women were between 25 and 50 years at diagno-
sis with a mean of 42 years. A description of this initial
study and the study sample are reported elsewhere [29].
In 2003 these women were recontacted to participate in a
follow-up study of long-term cancer survivorship specifi-
cally designed to obtain additional psychometric proper-
ties of the QLACS. Women were first sent a letter asking if
they could be recontacted. Of these women, 29 were dis-
covered to be deceased and 8 refused further contact. The
remaining women were then sent a cover letter describing
the study, along with the survey instrument and a
stamped return envelope. We attempted to locate as many
women as possible through use of address correction
requests, website searches, and telephone books. After 2
weeks, the survey was re-mailed via Federal Express to
those who had not returned their survey. Use of Federal
Express provided verification of whether a correct address
was available. Participants who did not return their survey
after two attempts were contacted by telephone, if aHealth and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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phone number was available. Those who completed the
survey were then sent an additional survey two weeks later
to assess test-retest reliability of the QLACS. One year later
study participants were sent a follow-up survey to assess
stability and responsiveness of the QLACS. The study
timeline is shown in Figure 1.
Measures
Table 1 shows when each measure was administered.
Quality of Life in Adult Cancer Survivors (QLACS)
The QLACS is designed to measure HRQL among long-
term cancer survivors. It contains 47 items and 12
domains; 7 are considered generic and 5 cancer-specific.
Generic domains include those that are not necessarily
attributable to cancer – Physical Pain, Negative Feelings,
Positive Feelings, Cognitive Problems, Sexual Problems,
Social Avoidance, and Fatigue. Cancer-specific domains
relate specifically to having had cancer and include Finan-
cial Problems resulting from cancer, Distress about Fam-
ily, Distress about Recurrence, Appearance Concerns, and
Benefits of Cancer. Previous factor analyses showed that a
7-factor solution for the generic domains was consistent
with the definition of the domains [22]. Accordingly, a
Generic summary score is formed by adding its 7 constit-
uent domain scores (reversing the score for Positive Feel-
Timeframe for Assessments Figure 1
Timeframe for Assessments.
  Year     Assessment 
 
 
1995 
  T0 
2003 
FU 1 
 
         2003 
         FU 2 
 (2 wks. later)   
    
         2004 
         FU 3 
 
Figure 1.   
Baseline 
FACT-B 
Symptoms, self-assessed health, missed work, 
coping, preparedness, sociodemographics,  
medical factors 
N=202 
8 yr. FU 
QLACS. FACT-B, SF-36 
Symptoms, self-assessed health, medical 
factors 
N=94 
2 wk. FU 
QLACS, FACT-B, SF-36 
Life changes 
N=83 
1 yr. FU 
QLACS, FACT-B, SF-36 
Life changes 
N=83 Health and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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ings). A separate factor analysis for cancer-specific
domains showed that Benefit of Cancer did not load with
the other domains. As a result, a Cancer-Specific summary
score is created by adding the constituent domains scores
except Benefit of Cancer. The score for Benefit of Cancer is
reported separately. We continue to follow this frame-
work in this report. The QLACS had not been developed
at the time of the baseline assessment and was only
administered at the follow-up interviews.
SF-36
The Medical Outcomes Short-Form Health Survey (SF-36)
is a validated generic instrument for measuring current
health status [30]. The survey form contains 36 items that
cover 8 dimensions of health: physical functioning, role
limitations due to physical problems, bodily pain, general
health perception, vitality, social functioning, role limita-
tions due to emotional problems, and mental health. The
score for each dimension is between 0 (worst) and 100
(best). The SF-36 was administered at follow-up as a com-
parison measure to the QLACS.
Functional Assessment of Cancer Therapy-Breast (FACT-B)
The Functional Assessment of Cancer Therapy for Breast
Cancer [31] was used as a cancer-specific HRQL compari-
son. The FACT-B consists of the following subscales: phys-
ical well-being, functional well-being, emotional well-
being, social/family well-being, and breast cancer specific
concerns. A total FACT-B score is calculated by summing
the subscales. The instrument has a total of 36 items ask-
ing respondents to rate how true each statement is for the
past 7 days. Response scales range from 0 (not at all) to 4
(very much). The FACT-B has been shown to have high
internal consistency, reliability, and has been well-vali-
dated [23]. Since we questioned whether the FACT-B was
its relevant for long-term survivors, we asked women to
indicate on the questionnaire any items that no longer
seemed relevant.
Global Quality of Life
A 100 mm Visual Analog Scale (VAS) was used to assess
global quality of life. The VAS is a validated, single item
measure [26,32] that asks respondents to rate their overall
quality of life in the past 2 weeks on a scale of 1–100
where 1 represents the lowest possible QOL and 100 the
represents the highest QOL.
Life Changes
A list of life change items assessed how various aspects of
life changed when compared to a specified time point
(e.g., 2 wks. ago or one year ago). These items were
included at FU2 and FU3 so that test-retest reliability and
responsiveness of the QLACS could be determined
according to whether or not women reported life changes.
The list was developed to tap areas directly related to the
dimensions of the QLACS: physical pain, mood, cognitive
problems, sexual problems, social functioning, fatigue,
financial problems, family-related concerns about cancer,
worries about recurrence, feelings about appearance from
having cancer, and feelings about positive aspects of hav-
ing cancer. The list also included a question on overall
QOL. Response options ranged from 1 "quite a bit worse"
to 5 "quite a bit better
Medical History
Medical/treatment variables at baseline included type of
initial surgery (lumpectomy, mastectomy, reconstruc-
tion), type of treatment (chemotherapy, radiation, hor-
monal), current treatment, and recurrence. Other
questions inquired about age at diagnosis, time since
Table 1: Timeframe for measures
Baseline (T0)
1995
N = 202
FU1
2003
N = 94
FU2
2003
(2 weeks after FU1)
N = 83
FU3
2004
(One year after FU1)
N = 83
Global QOL (VAS) X X X X
FACT-B X X X X
QLACS X X X
SF-36 X X
Symptoms X X
Self Assessed Health X X
Days Missed Work or Usual Activity X
Coping X
Preparedness X
Sociodemographics X X
Medical factors X X X
Life change items XXHealth and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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diagnosis, and time since end of treatment. Subsequent
surveys asked about surgeries, treatments, and recurrences
since baseline.
Other Measures
The following measures were cross-sectionally related to
the FACT-B at baseline [29] and used in the present study
for the retrospective validity analyses.
Symptoms
Women were given a list of 14 symptoms derived from the
Breast Cancer Prevention Trial Symptom Checklist
[33,34] and asked to rate how bothered they had been by
each symptom in the past 4 weeks. Responses ranged
from 1 = "not at all" to 5 "very much." Symptoms
included in the present analyses were hot flashes, nausea,
vomiting, diarrhea, difficulty with bladder control when
laughing or crying, difficulty with bladder control at other
times, vaginal discharge, vaginal dryness, pain with sexual
intercourse, swelling of hands and feet, general aches and
pains, unhappiness with appearance, weight gain, and
weight loss. Symptom scores were summed to provide an
overall score.
Self-assessed health
This was the widely used single item where respondents
rate their health on a 5-point scale from excellent to poor.
Days of work/Usual activity missed
Women were asked to indicate the number of days of
work or usual activity that they missed in the first 3
months following diagnosis.
Coping
Thirty-two items from the Ways of Coping-Cancer Version
(WOC-CA) were used to assess coping strategies [35]. This
measure and our modification are described in detail else-
where [36]. Study participants were asked to indicate how
often they had used each strategy in the past six months in
attempting to cope with the most stressful part of their
breast cancer. Previous factor analyses based on the base-
line sample revealed seven scales or coping strategies.
Four of these scales were related to HRQL at baseline, as
measured by the FACT-B: seek and use social support, pos-
itive cognitive restructuring, wishful thinking, and made
changes.
Preparedness
Three items assessed feelings of preparedness for coping
with different aspects of breast cancer. Women were asked
how prepared they felt for coping with their breast cancer
and treatment in terms of the possible impact on their
relationships, how they might feel about their appearance
after surgery, and the availability of counseling or support
groups. These items were developed specifically for the
original project to inform future interventions. A factor
analysis revealed one dominant factor. We also found
high internal consistency among the items (Cronbach's
alpha = 0.79) which were summed to provide a single
measure.
Sociodemographic variables
Included in the survey were questions on current marital/
partner status, income, education, age, and employment
status. These items were asked at baseline and the first fol-
low-up.
Analysis
Internal consistency
(Cronbach's alpha) for each subscale of the QLACS was
assessed at each follow-up (FU1, FU2, and FU3). Test-
retest reliability of the QLACS was measured by compar-
ing FU1 and FU2 scores, which were administered 2 weeks
apart. Only respondents who reported no important life
change in the brief period between the two assessments
were included in the test-retest analysis. Both the Pearson
correlations and intraclass correlation coefficients (ICC)
were used to compare the test-retest reliability.
Concurrent validity
of the QLACS was assessed by analyzing correlations
between the QLACS domain and summary scores with
other HRQL measures: SF-36, FACT-B, and VAS. We
hypothesized that the QLACS Generic Summary score
would be strongly correlated with the other generic QOL
measures (e.g., SF-36, VAS), whereas the QLACS Cancer-
Specific Summary score would weakly correlate with these
measures. The Cancer-Specific summary score was
expected to achieve a higher level of correlation with the
Breast Cancer Specific Concerns of the FACT-B, which is
targeted for breast cancer patients.
Retrospective validity
assesses how well a measure retrospectively relates to fac-
tors that are hypothesized to be predictive of the measure.
In baseline analyses, we found that the following varia-
bles were highly related to HRQL as measured by the
FACT-B: the number of days of work or usual activity
missed in the 3 months following initial diagnosis; four
coping strategies – positive cognitive restructuring, seek-
ing and using social support, wishful thinking, and made
changes; and feeling prepared for the impact of cancer
[29]. We used these baseline variables to predict QLACS
scores at FU1.
Responsiveness
to change was examined using change in QLACS domain
scores 1-yr. apart (from FU1 to FU3). Domain change
scores were compared with direct reports of life changes
by respondents. The overall QOL item was used for theHealth and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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QLACS summary scores. Study participants were classified
into three groups according to their response to the Life
Change question – positive change (quite a bit better and
somewhat better), no change (about the same), and neg-
ative change (quite a bit worse and somewhat worse). An
ANOVA test was performed for the change score from
each domain to assess whether the differences between
the three groups were significant. The p-value, effect sizes
and reliable change index (RCI) [37] were used to meas-
ure the magnitude of responsiveness. RCI is defined as the
difference normalized by the standard error of measure-
ment. The following guidelines were used to characterize
effect sizes: <0.2 small changes; 0.2–0.5 moderate change;
above 0.5 large change; above 1.0 very large change [38].
An RCI larger than 1.96 is considered reliable change.
Because of the possible asymmetry between positive and
negative change, effect sizes and SEM were reported sepa-
rately for each direction.
Results
Sample characteristics
Of the 202 women who completed a baseline survey, 92
women completed follow-up surveys at FU1. Surveys were
not completed for the following reasons: deceased (n =
29), unable to locate (n = 53), refused (n = 8), did not
return survey (n = 17), and too ill (n = 1). An additional 9
women completed surveys at FU1, but not FU2 or FU3.
Our response rate was 78% of those who may have
received our mailings (we conservatively assume that
those surveys not returned by Federal Express were
received by participants) and 45.5% of the original sam-
ple. This response rate is comparable to other studies that
have re-contacted women after this length of time [39,40].
We compared those who completed the survey at FU1
with the full sample at baseline and found that those who
were not reached at follow-up were less likely to be part-
nered at baseline, but they did not differ on any other
sociodemographic or medical factors.
Table 2 shows the characteristics of the analytic sample
(FU1). The mean age of the sample was 51 years. Most
study participants were Caucasian (96%) and the majority
were employed (78%). Time since diagnosis ranged from
8.6 to 11.4 years with a mean of 9.9 years. Thirteen
women reported a recurrence since initial diagnosis and
seven experienced another cancer. Forty-six percent of
women had an initial mastectomy and more than half of
these women had reconstruction. An additional 10.6%
had a mastectomy following baseline and 18% had recon-
struction. Seventy-seven percent reported initial chemo-
therapy and 66% had radiation initially (some women
had both). Following baseline, close to 10% of women
had chemotherapy and about 7% had radiation.
Characteristics of the QLACS and reliability
Table 3 shows the mean domain scores and possible floor
and ceiling effects of the QLACS at FU1. Domains gener-
ally showed low floor or ceiling effects with financial
problems being the only domain to demonstrate a floor
effect where 61% of the sample reported no financial
problems. A comparison between these scores and those
of the breast cancer sample from the original QLACS
paper revealed the only significant difference was for neg-
ative feelings. The present sample was significantly higher
on negative feelings (11.5 compared with 9.7; p = .01).
All test-retest correlations exceed the commonly used
standard of 0.7 for testing reproducibility. The ICCs were
respectively 0.95 and 0.98 for the two summary scales.
The value of Cronbach's alpha at the three time points for
domains ranged from 0.72 to 0.95 (data not shown).
Most of the alpha values (33 of 36) were well over 0.8,
suggesting that domains had a high level of internal con-
sistency [41].
Concurrent and retrospective validity
Table 4 shows the results of our concurrent validity anal-
yses. All of the generic QLACS subscales correlated highly
with the equivalent subscale of the SF-36. The QLACS
Generic Summary (GSS) score was highly correlated with
the SF-36 PCS and MSC component dimensions (ρ = -
0.70, -0.69 respectively) and with the FACT-G (r = -.81).
The correlation between the GSS score and three other
measures – VAS, total symptom score, and self-assessed
health were similar (ρ = -0.72, 0.58, and 0.67, respec-
tively.)
As would be expected, the QLACS Cancer-Specific sum-
mary (CSS) score had a weaker correlation with the PCS
and MCS component scores (ρ = -0.32, -0.39) and the
VAS, total symptom score, and self assessed health (ρ = -
0.32, 0.46, and 0.38 respectively). The QLACS CSS score
showed a greater correlation with the FACT Breast Cancer
Specific Concerns subscale (-0.62), which focuses on
breast cancer.
These results suggest that the GSS has convergent validity
with measures designed to assess generic QOL and the
CSS score exhibits divergent validity with generic QOL
measures, but not the FACT- B.
We examined retrospective validity by evaluating how
well the QLACS at FU1 correlated with factors that were
known to be significantly associated with HRQL, meas-
ured 8 years earlier at baseline (T0) by the FACT-B. The
results reported in Table 5 show that three of the baseline
variables (days work/usual activity missed, wishful think-
ing, and preparedness) were good predictors of the
QLACS CSS score and better predictors of the QLACS CSSHealth and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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than of the FACT-B. Positive cognitive restructuring at
baseline was a better predictor of the FACT-B and the
QLACS GSS.
Responsiveness
For each domain and the summary score, responsiveness
was gauged by comparing the QLACS change scores at
FU1 and one-year later (FU3) with change in health status
The mean change scores, effect sizes, and RCIs are
reported in Table 6 by direction of self-reported change –
worse, or better. Generally, the QLACS demonstrated a
high level of responsiveness to life change. All directions
of effect size and RCI are consistent with the direction of
change in health. Judging by p-values, four domains
would be considered not very responsive: Cognitive Prob-
lems, Sexual Problems, Family Distress, and Recurrent
Distress, though some of the effect sizes could still be con-
sidered moderate.
Discussion
Despite the importance of HRQL for long-term survivors,
there are currently only two HRQL measures designed
specifically for long-term survivors, one of which is a
modification of the other. Researchers at the City of Hope
National Medical Centre were originators in developing a
HRQL measure for long-term survivors. They developed
the Quality of Life-Cancer Survivors scale (QOL-CS)
based on their conceptualization of HRQL as having four
Table 2: Characteristics of FU1 analytic sample n = 94
Characteristic % (n) Mean (sd)
Sociodemographics
Age (years) 51.4 (6.2)
38–44 16.0% (15)
45–50 21.3% (20)
51–55 28.7% (27)
56–61 34.0% (32)
Current partner status:
No partner 12.8 (12)
Marriage-like partner 7.4 (7)
Married 79.8 (75)
Educational level:
High school or less 18.1 (17)
Some college 56.4 (53)
Post-college 25.5 (24)
Employed 77.7 (73)
Medical Factors
Initial mastectomy/reconstruction:
No mastectomy 54.2 (51)
Mastectomy, no reconstruction 21.3 (20)
Mastectomy, reconstruction 24.5 (23)
Initial chemotherapy:
No 23.4 (22)
Yes 76.6 (72)
Initial radiation therapy:
No 34.4 (32)
Yes 65.6 (61)
Age at diagnosis (years) 41.61 (6.07)
Time since diagnosis (mean) 9.9 years
Currently undergoing treatment
No 88.3 (83)
Yes 11.7 (11)
Treatment since baseline
Mastectomy since baseline 10.6 (10)
Reconstruction since baseline 18.1 (17)
Chemotherapy since baseline 9.6 (9)
Radiation since baseline 7.4 (7)
Recurrence since baseline 13.8 (13)
Other cancer since baseline 7.4 (7)
General health (5-point scale) 2.29 (0.95)
Total Symptom Score 26.3 (2.2)
Overall quality of life (visual analogue) 70.0 (20.8)Health and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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dimensions: physical, psychological, social, and spiritual
[27]. Although this scale reflects an attempt to recognize
HRQL issues relevant to long-term cancer survivors, it has
a number of limitations. Items were based on a small
number of cancer survivors and validation of the scale was
based on survivors ranging from 4 months to 28 years
after diagnosis (thus including newly diagnosed patients).
Some items have problematic wording, in that they ask
about change but fail to indicate its direction (e.g., "has
your illness or treatment caused changes in your self-con-
cept?"). The domains often measure multiple constructs
at once (e.g., social interaction includes appearance, sex-
Table 4: Correlation coefficients between QLACS scores and other measures
QLACS scale Measure Correlation
Subscales
Physical Pain SF36 – Bodily pain -0.82
Negative Feelings SF-36 mental health -0.78
Positive Feelings SF-36 mental health -0.81
Cognitive Problems N/A -
Sexual Problems N/A -
Social Avoidance SF-36 Social functioning -0.71
Fatigue SF-36 Vitality -0.88
QLACS generic summary score (GSS) SF-36 PCS -0.70
SF-36 MCS -0.69
FACTG -0.81
VAS -0.72
Symptoms 0.58
Self-Assessed Health 0.67
QLACS cancer specific summary score (CSS) SF-36 PCS -0.32
SF-36 MCS -0.39
FACT Breast Cancer Specific Subscale -0.62
VAS -0.32
Symptoms 0.46
Self-assessed health 0.38
*The N for correlations is from 88 to 94.
Table 3: Descriptive summary of distribution of QLACS summary and domain scores, possible floor and ceiling effects at FU1, test-
retest correlation, and ICC between FU1 and FU2,
Domain/Subscale N Mean STD Min % Floor Max % Ceiling Test-retest Correlation ICC
Generic
Negative Feelings 94 11.5 4.2 4 1.1 27 0 0.78 -
Positive Feelings 94 20.8 5.1 7 0 28 2.1 0.82 -
Cognitive Problems 94 10.6 4.3 4 5.3 24 0 0.75 -
Sexual Problems 91 13.7 6.6 4 6.4 28 2.1 0.89 -
Physical Pain 93 8.5 5.0 4 20.1 26 0 0.89 -
Fatigue 94 12.3 5.6 4 4.3 27 0 0.84 -
Social Avoidance 94 7.9 4.6 4 0 26 0 0.86 -
Summary** 93 75.5 26.3 49 0 167 0 0.91 0.95
Cancer-Specific
Appearance 94 8.2 4.9 4 29.8 24 0 0.83 -
Financial Problems 93 6.2 3.9 4 60.6 25 0 0.82 -
Distress – Recurrence 94 11.7 5.7 4 10.6 28 1.1 0.85 -
Distress – Family 94 10.9 6.7 4 17.0 28 2.1 0.88 -
Summary 94 37.0 15.7 16 2.13 90 0 0.89 0.98
Benefit of Cancer 94 17.6 6.2 4 2.13 28 4.3 0.82 -
N.B. – Missing percentage are low in general. The domain that contains most missing values is Sexual Problem, in which there are 3 missing values 
(3.2%). Lower scores equal better quality of life.
**The summary score is computed by added the domain scores except for positive feelings. The positive feelings score is subtracted from 32 and 
then added to the other domain scores.Health and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
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ual functioning, and family distress). Further, several
items ask about distress at the time of diagnosis and treat-
ment.
Wyatt and colleagues [15] developed the Long-term Qual-
ity of Life (LTQL) questionnaire based on the same con-
ceptual model. Based on data from a sample of female
cancer survivors, they conducted a factor analysis, an
internal consistency analysis, and determined content
validity. These results yielded 34 items loading on 4 fac-
tors that are slightly different from the QOL-CS: somatic
concerns, spiritual/philosophical view of life, fitness, and
social support. While the psychometric approach of the
LTQL is an advantage,, some of the items themselves are
still problematic and the domains often encompass more
than one important aspect of HRQL. For example, the
somatic concerns domain includes both body-image
problems and pain. Type of cancer and its treatment may
well vary in terms of their impact on these two concerns.
The broad domains do not allow investigators to look at
more specific HRQL areas.
The QLACS was developed in response to these limita-
tions. The analyses reported here suggest that the QLACS
has good internal consistency reliability, and adequate
concurrent and retrospective validity. Responsiveness to
change is encouraging, but needs more testing in other
samples.
Important findings of this study include the concurrent
and retrospective validity of both the Generic Summary
score and the Cancer-Specific Summary score in assessing
HRQL of long term cancer survivors. We found that the
Generic Summary score tracks well with some existing
generic measures, while the Cancer-Specific Summary
Score showed a much lower correlation with other generic
QOL measures. Compared to other instruments, the Can-
cer-Specific Summary score exhibits relatively high predic-
tive validity as judged by its associations with number of
missed days of work/usual activity following diagnosis,
the respondent's feelings of preparedness for dealing with
Table 6: Responsiveness in terms of p-value, effect size, and reliable change index in either positive or negative direction
Group with negative change Group with positive change
Domain Overall F test in ANOVA p N Effect Size Reliable change index N Effect Size Reliable change index
Generic summary 0.02 9 0.83 2.75 29 -0.09 -0.31
Physical Pain 0.001 21 0.63 1.81 9 -0.18 -0.51
Negative Feelings 0.001 12 0.79 1.77 28 -0.29 -0.65
Positive Feelings <0.001 12 -0.97 -2.23 27 0.36 0.84
Cognitive Problems 0.21 13 0.34 0.69 5 -0.32 -0.66
Sexual Problems 0.24 11 0.13 0.39 9 -0.38 -1.14
Social Avoidance <0.001 9 1.07 2.98 9 -0.67 -1.85
Fatigue 0.04 15 0.36 1.00 10 -0.13 -0.36
Cancer-Specific summary 0.023 9 0.66 2.10 30 -0.06 -0.20
Financial Problems 0.048 21 0.52 1.11 15 -0.11 -0.23
Family Distress 0.21 13 0.15 0.42 5 -0.43 -1.23
Recurrence Distress 0.40 14 0.30 0.75 7 0.05 0.13
Appearance Concerns <0.0001 6 1.43 3.46 7 -0.31 -0.74
Benefit of Cancer 0.032 5 -0.26 -0.62 8 0.66 1.55
Table 5: Retrospective correlation between measures at baseline (T0) and measures of QOL at FU01. The number in parenthesis is p-
value
Baseline Measure Generic Summary score Cancer-Specific Summary score FACT-B
r (p) r (p) r (p)
Days work/usual activity missed 
following diagnosis
-0.01 (0.92) 0.25 (0.01) -0.18 (0.09)
Positive cognitive restructuring -0.24 (0.02) -0.13 (0.21) 0.21 (0.04)
Wishful thinking 0.14 (0.20) 0.38 (0.0001) -0.21 (0.05)
Preparedness for cancer 0.10 (0.34) 0.38 (0.0001) -0.17 (0.11)
Seek social support -0.02 (0.81) 0.03 (0.80) -0.02 (0.82)
Made changes -0.16 (0.13) -0.15 (0.17) 0.17 (0.10)
*The N for correlations is from 88–94.Health and Quality of Life Outcomes 2006, 4:92 http://www.hqlo.com/content/4/1/92
Page 10 of 11
(page number not for citation purposes)
cancer, and coping strategies. For example, the number of
days missing work has a strong significant correlation
with the QLACS CSS, suggesting that women who tend to
miss a high number of workdays or usual activity imme-
diately following diagnosis have a lower QOL several
years later. Women who reported being well prepared
(responded with 4 or 5 on the preparedness scale) showed
substantially better quality of life when projected to sev-
eral years later in the QLACS CSS measure than the FACT-
B. These retrospective validity results suggest that the
QLACS had better predictive validity than the FACT-B.
Our qualitative data suggests that some of the FACT-B
items may not be relevant for long-term survivors. Despite
answering all of the items, 52 women indicated that at
least one FACT question was no longer relevant to them.
This occurred most frequently for questions about pain
(N = 30), side effects of treatment (N = 29), nausea (N =
14), and family communication about illness (N = 14).
We should point out, however, that we did not ask
respondents to indicate when QLACS questions were not
relevant.
It is also worth comparing the QLACS scores in this sam-
ple with those of the breast cancer sample in the original
QLACS paper. The only domain score that was signifi-
cantly different was negative feelings, with the younger
sample reporting greater negative feelings. This finding is
consistent with other research showing greater psycholog-
ical morbidity among younger women with breast cancer
[42-44].
The QLACS was generally responsive to self-reported
changes. One finding about this population of long-term
survivors is the absence of detectable changes in HRQL in
several domains – Cognitive Problems, Sexual Problems,
Family Distress, and Recurrence Distress (all p > 0.20),
even when a change in these areas had been reported.
There may be several explanations for this. While it is pos-
sible that the QLACS is not sufficiently responsive in these
domains, the absence of detectable changes could also be
due to this particular sample or the nature of the life
change questions. More clinical measures might show
greater responsiveness. We also observe that the instru-
ment tends to be more responsive to negative changes. For
example, for respondents reporting "Somewhat worse" or
"Quite a bit worse" in wanting to socialize (Social Avoid-
ance domain), the effect size was 2.98, compared to an
effect size of 1.85 for the group that reported "Somewhat
better" or "Quite a bit better" for wanting to socialize. It is
important to continue evaluation of the responsiveness of
the QLACS in different samples. To our knowledge, how-
ever, we are unaware of responsiveness data by domain
for other scales such as the FACT.
There are several limitations of this study. The analyses
reported here are based on a follow-up of well-educated,
young, white female breast cancer survivors. Studies need
to be conducted among more diverse samples of survivors
of different ethnicities, ages, and cancers to gather more
data on the usefulness of the QLACS for other cancer sur-
vivors. Another limitation of this work is the number of
women lost to follow-up. Finally, our responsiveness data
were limited to self-reported life. More research using clin-
ical measures or clinical trial data to assess responsiveness
is desirable. Nevertheless, the QLACS may be a a useful
measure for assessing HRQL among long term cancer sur-
vivors and warrants further evaluation.
Conclusion
The QLACS appears to be a promising measure to assess
HRQL among long-term breast cancer survivors and war-
rants further evaluation
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